23/06/2022at 13:50

GSK to invest USD 1.2bn in infectious disease battle

The UK drugmaker has joined a string of pharmaceutical firms that are responding to a call of action concerning future drug resistance.

By James Paton, bloomberg

GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Drugmakers aim to curb release of antibiotic waste into the environment
For subscribers
EMA publishes new plan to support antibiotic development
For subscribers
Carb-X secures USD 370m in fight against antibiotic resistance
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

EU weighs plan to incentivize drugmakers to fight superbugs

A Netflix-style subscription model following the UK’s example could incentivize antibiotic making to curb to the increasingly gloomy prospects of drug-resistant infections.

For subscribers

Regulation

Blockbuster weight-loss drug Wegovy to be available on NHS

Danish drugmaker Novo Nordisk’s obesity treatment, Wegovy, is headed to UK patients through the NHS – though the drug is recommended for obesity patients alongside lifestyle changes.

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

GSK to invest USD 1.2bn in infectious disease battle

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Drugmakers aim to curb release of antibiotic waste into the environment

EMA publishes new plan to support antibiotic development

Carb-X secures USD 370m in fight against antibiotic resistance

Sign up for our newsletter

Front page now

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Further reading

EU weighs plan to incentivize drugmakers to fight superbugs

Blockbuster weight-loss drug Wegovy to be available on NHS

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Jobs